Objective: To present baseline and interim results from the SHINE study (NCT02594124) for participants with later-onset SMA (most likely to develop Type II or III SMA) who transitioned from CHERISH.
, and 10.0 (6-20) months; 50%, 50% and 55% were female, respectively. Mean baseline (SD) WHO motor milestones was 1.5 (1.02), 1.4 (1.11) and 1.4 (0.96); mean (SD) HFMSE score was 19.9 (7.23), 19.8 (8.39), and 22.4 (8.33), in the 3 groups respectively. Results from an interim analysis with an October 15, 2018 data cutoff will be presented.
Conclusions:
Continued analysis of data from children treated with nusinersen via the SHINE study will increase the information available on the long-term safety/tolerability and efficacy of repeated nusinersen doses.
